Second Line Breast Cancer Trial

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Anastrozole; Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• postmenopausal women with confirmation of breast cancer

• objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer

Exclusion Criteria:

• presence of life-threatening metastatic visceral disease

• previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer

• more than 1 prior endocrine medical treatment for advanced breast cancer .